Is OLMA or TNGX more profitable?

Tango Therapeutics' return on equity of -41.54% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -46.00% -41.22% Tango Therapeutics N/A -41.54% -33.44%

Does the media refer more to OLMA or TNGX?

In the previous week, Tango Therapeutics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 4 mentions for Tango Therapeutics and 2 mentions for Olema Pharmaceuticals. Tango Therapeutics' average media sentiment score of 1.57 beat Olema Pharmaceuticals' score of 1.07 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to NAMS or OLMA?

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 3 mentions for NewAmsterdam Pharma and 2 mentions for Olema Pharmaceuticals. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Olema Pharmaceuticals' score of 1.07 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OLMA or DNLI more profitable?

Olema Pharmaceuticals' return on equity of -46.00% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -46.00% -41.22% Denali Therapeutics N/A -52.20% -43.86%

Does the media refer more to OLMA or DNLI?

In the previous week, Denali Therapeutics had 9 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 11 mentions for Denali Therapeutics and 2 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.07 beat Denali Therapeutics' score of 0.78 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, TLX or OLMA?

Telix Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.63 -$7.12M N/A N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A

Is TLX or OLMA more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Olema Pharmaceuticals N/A -46.00% -41.22%

Does the media refer more to TLX or OLMA?

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 2 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.07 beat Telix Pharmaceuticals' score of 0.47 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, GPCR or OLMA?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A

Is GPCR or OLMA more profitable?

Structure Therapeutics' return on equity of -24.91% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% Olema Pharmaceuticals N/A -46.00% -41.22%

Does the media prefer GPCR or OLMA?

In the previous week, Structure Therapeutics and Structure Therapeutics both had 2 articles in the media. Structure Therapeutics' average media sentiment score of 1.61 beat Olema Pharmaceuticals' score of 1.07 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Olema Pharmaceuticals (OLMA) Competitors

$11.85 -0.06 (-0.50%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$11.85 0.00 (0.00%)

As of 07/13/2026 06:18 PM Eastern

Compare

OLMA vs. TNGX, NAMS, DNLI, TLX, and GPCR

Should you buy Olema Pharmaceuticals stock or one of its competitors? MarketBeat compares Olema Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Olema Pharmaceuticals include Tango Therapeutics (TNGX), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), Telix Pharmaceuticals (TLX), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

How does Olema Pharmaceuticals compare to Tango Therapeutics?

Olema Pharmaceuticals (NASDAQ:OLMA) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Olema Pharmaceuticals presently has a consensus price target of $44.10, indicating a potential upside of 272.15%. Tango Therapeutics has a consensus price target of $41.50, indicating a potential upside of 46.33%. Given Olema Pharmaceuticals' higher probable upside, equities research analysts clearly believe Olema Pharmaceuticals is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Tango Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Tango Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Tango Therapeutics	$62.38M	65.76	-$101.59M	-$0.83	N/A

Olema Pharmaceuticals has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

In the previous week, Tango Therapeutics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 4 mentions for Tango Therapeutics and 2 mentions for Olema Pharmaceuticals. Tango Therapeutics' average media sentiment score of 1.57 beat Olema Pharmaceuticals' score of 1.07 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Tango Therapeutics' return on equity of -41.54% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Tango Therapeutics	N/A	-41.54%	-33.44%

Summary

Tango Therapeutics beats Olema Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 3 mentions for NewAmsterdam Pharma and 2 mentions for Olema Pharmaceuticals. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Olema Pharmaceuticals' score of 1.07 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NewAmsterdam Pharma presently has a consensus price target of $49.00, indicating a potential upside of 47.24%. Olema Pharmaceuticals has a consensus price target of $44.10, indicating a potential upside of 272.15%. Given Olema Pharmaceuticals' higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Olema Pharmaceuticals has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

NewAmsterdam Pharma has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market.

Olema Pharmaceuticals has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	172.91	-$203.82M	-$1.79	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Summary

NewAmsterdam Pharma beats Olema Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Denali Therapeutics?

Olema Pharmaceuticals (NASDAQ:OLMA) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Olema Pharmaceuticals has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Olema Pharmaceuticals currently has a consensus target price of $44.10, indicating a potential upside of 272.15%. Denali Therapeutics has a consensus target price of $34.75, indicating a potential upside of 31.23%. Given Olema Pharmaceuticals' higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

Olema Pharmaceuticals' return on equity of -46.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Denali Therapeutics	N/A	-52.20%	-43.86%

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Olema Pharmaceuticals has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Denali Therapeutics	$330.53M	12.71	-$512.54M	-$2.88	N/A

In the previous week, Denali Therapeutics had 9 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 11 mentions for Denali Therapeutics and 2 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.07 beat Denali Therapeutics' score of 0.78 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Olema Pharmaceuticals beats Denali Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Telix Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.63	-$7.12M	N/A	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 7 mentions for Telix Pharmaceuticals and 2 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.07 beat Telix Pharmaceuticals' score of 0.47 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

Telix Pharmaceuticals currently has a consensus target price of $21.00, suggesting a potential upside of 91.43%. Olema Pharmaceuticals has a consensus target price of $44.10, suggesting a potential upside of 272.15%. Given Olema Pharmaceuticals' higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Telix Pharmaceuticals' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Summary

Telix Pharmaceuticals beats Olema Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

Structure Therapeutics presently has a consensus target price of $110.55, suggesting a potential upside of 114.07%. Olema Pharmaceuticals has a consensus target price of $44.10, suggesting a potential upside of 272.15%. Given Olema Pharmaceuticals' higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Structure Therapeutics has a beta of -1.5, meaning that its stock price is 250% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

In the previous week, Structure Therapeutics and Structure Therapeutics both had 2 articles in the media. Structure Therapeutics' average media sentiment score of 1.61 beat Olema Pharmaceuticals' score of 1.07 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Structure Therapeutics' return on equity of -24.91% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Summary

Structure Therapeutics beats Olema Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get Olema Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OLMA vs. The Competition

Export

Metric	Olema Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.04B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-5.87	20.85	27.11	24.26
Price / Sales	N/A	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	2.02	8.49	10.75	6.29
Net Income	-$162.45M	$23.83M	$3.58B	$330.66M
7 Day Performance	-6.18%	-3.56%	-2.06%	-1.32%
1 Month Performance	20.06%	6.31%	3.32%	-0.64%
1 Year Performance	145.34%	48.30%	26.36%	19.08%

Olema Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OLMA Olema Pharmaceuticals	2.3471 of 5 stars	$11.85 -0.5%	$44.10 +272.2%	+154.8%	$1.04B	N/A	N/A	70	Analyst Upgrade
TNGX Tango Therapeutics	2.9573 of 5 stars	$29.75 -0.6%	$41.50 +39.5%	+378.2%	$4.30B	$56.99M	N/A	90	Positive News
NAMS NewAmsterdam Pharma	3.3734 of 5 stars	$35.56 +1.9%	$49.00 +37.8%	+54.5%	$4.15B	$22.57M	N/A	4	News Coverage
DNLI Denali Therapeutics	3.2886 of 5 stars	$26.20 +1.8%	$34.25 +30.7%	+82.4%	$4.15B	$330.53M	N/A	430	Analyst Forecast
TLX Telix Pharmaceuticals	4.5837 of 5 stars	$11.72 -3.5%	$21.13 +80.2%	-31.3%	$3.98B	$803.79M	N/A	1,184

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OLMA) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. TNGX, NAMS, DNLI, TLX, and GPCR

How does Olema Pharmaceuticals compare to Tango Therapeutics?

Summary

How does Olema Pharmaceuticals compare to NewAmsterdam Pharma?

Summary

How does Olema Pharmaceuticals compare to Denali Therapeutics?

Summary

How does Olema Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does Olema Pharmaceuticals compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. TNGX, NAMS, DNLI, TLX, and GPCR

How does Olema Pharmaceuticals compare to Tango Therapeutics?

Do institutionals and insiders believe in OLMA or TNGX?

Do analysts prefer OLMA or TNGX?

Which has preferable earnings & valuation, OLMA or TNGX?

Which has more volatility and risk, OLMA or TNGX?

Does the media refer more to OLMA or TNGX?

Is OLMA or TNGX more profitable?

Summary

How does Olema Pharmaceuticals compare to NewAmsterdam Pharma?

Does the media refer more to NAMS or OLMA?

Do insiders & institutionals hold more shares of NAMS or OLMA?

Do analysts prefer NAMS or OLMA?

Is NAMS or OLMA more profitable?

Which has more risk and volatility, NAMS or OLMA?

Which has preferable earnings & valuation, NAMS or OLMA?

Summary

How does Olema Pharmaceuticals compare to Denali Therapeutics?

Which has more risk & volatility, OLMA or DNLI?

Do analysts rate OLMA or DNLI?

Is OLMA or DNLI more profitable?

Do institutionals & insiders believe in OLMA or DNLI?

Which has higher earnings and valuation, OLMA or DNLI?

Does the media refer more to OLMA or DNLI?

Summary

How does Olema Pharmaceuticals compare to Telix Pharmaceuticals?

Do institutionals and insiders hold more shares of TLX or OLMA?

Which has better earnings and valuation, TLX or OLMA?

Does the media refer more to TLX or OLMA?

Which has more volatility and risk, TLX or OLMA?

Do analysts prefer TLX or OLMA?

Is TLX or OLMA more profitable?

Summary

How does Olema Pharmaceuticals compare to Structure Therapeutics?

Do analysts rate GPCR or OLMA?

Which has more volatility & risk, GPCR or OLMA?

Does the media prefer GPCR or OLMA?

Which has higher earnings and valuation, GPCR or OLMA?

Do institutionals & insiders hold more shares of GPCR or OLMA?

Is GPCR or OLMA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools